Cardiogenic shock in ACS. Part 1: Prediction, presentation and medical therapy

Nature Reviews Cardiology

Volumn 9, Issue 3, 2012, Pages 158-171

  Westaby, Stephen ^a   Kharbanda, Rajesh ^b   Banning, Adrian P ^b  

^a Departments of Cardiothoracic Surgery   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERTENSIVE AGENT; INOTROPIC AGENT; INTERLEUKIN 6; LACTIC ACID; LEVOSIMENDAN; N(G) METHYLARGININE; NITRIC OXIDE; NORADRENALIN; SILDENAFIL; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AORTA BALLOON; ASSISTED CIRCULATION; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CORONARY REPERFUSION; CORONARY STENT; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REVASCULARIZATION; HEART OUTPUT; HEART RUPTURE; HUMAN; INDUCED HYPOTHERMIA; INFLAMMATION; LACTATE BLOOD LEVEL; LOADING DRUG DOSE; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MITOCHONDRIAL RESPIRATION; MITRAL VALVE REGURGITATION; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; POSITIVE END EXPIRATORY PRESSURE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; VASCULAR RESISTANCE;

ACUTE CORONARY SYNDROME; HUMANS; HYPOTHERMIA, INDUCED; INCIDENCE; INFLAMMATION MEDIATORS; MYOCARDIAL ISCHEMIA; RISK FACTORS; SHOCK, CARDIOGENIC; VENTRICULAR SEPTAL RUPTURE;

EID: 84857650819     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.194     Document Type: Review

References (94)

1. Hasdai, D., Topol, E. J., Califf, R. M., Berger, P. B. & Holmes, D. R. Jr. Cardiogenic shock complicating acute coronary syndromes. Lancet 356, 749-756 (2000). (Pubitemid 30663268)
2. Thom, T. et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Committee. Circulation 113, e85-e151 (2006).
3. Hochman, J. S. et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation 91, 873-881 (1995).
4. Hochman, J. S. et al. Early revascularisation in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N. Engl. J. Med. 341, 625-634 (1999).
5. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N. Engl. J. Med. 336, 1621-1628 (1997).
6. Grines, C. L. et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N. Engl. J. Med. 328, 673-679 (1993). (Pubitemid 23073368)
7. Jeger, R. V. et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann. Intern. Med. 149, 618-626 (2008).
8. Fang, J., Mensah, G. A., Alderman, M. H. & Croft, J. B. Trends in acute myocardial infarction complicated by cardiogenic shock 1979-2003, United States. Am. Heart J. 152, 1035-1041 (2006). (Pubitemid 44854794)
9. Singh, M. et al. Long-term outcome and its predictors among patients with ST segment elevation myocardial infarction complicated by shock: insights from the GUSTO 1 trial. J. Am. Coll. Cardiol. 50, 1752-1758 (2007). (Pubitemid 47600588)
10. Hochman, J. S. et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 295, 2511-2515 (2006). (Pubitemid 43854966)
11. Holmes, D. R. Jr. et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO I trial experience. The GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J. Am. Coll. Cardiol. 26, 668-674 (1995).
12. John, R. et al. Experience with the Levitronix CentriMag circulatory support system as bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J. Thorac. Cardiovasc. Surg. 134, 351-358 (2007). (Pubitemid 47088583)
13. Sheu, J. J. et al. Early extra corporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit. Care Med. 38, 1810-1817 (2010).
14. Webb, J. G. et al. Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK trial registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J. Am. Coll. Cardiol. 36, 1084-1090 (2000).
15. Hochman, J. S. et al. Cardiogenic shock complicating acute myocardial infarction - etiologies, management and outcome: a report from the SHOCK trial registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J. Am. Coll. Cardiol. 36, 1063-1070 (2000).
16. Menon, V. et al. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure. A report from the SHOCK trial registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J. Am. Coll. Cardiol. 36, 1071-1076 (2000).
17. Hasdai, D. et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST segment elevation. J. Am. Coll. Cardiol. 36, 685-692 (2000).
18. Kohsaka, S. et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch. Intern. Med. 165, 1643-1650 (2005). (Pubitemid 41124160)
19. Hochman, J. S. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 107, 2998-3002 (2003). (Pubitemid 36758968)
20. Patel, M. R. et al. Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL trial). Am J Cardiol. 95, 614-618 (2005). (Pubitemid 40255251)
21. Geppert, A. et al. Plasma concentrations of interleukin 6, organ failure, vasopresser support and successful coronary revascularisation in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit. Care Med. 34, 2035-2042 (2006). (Pubitemid 44305602)
22. Cotter, G. et al. LINCS: L NAME (a No Synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur. Heart J. 24, 1287-1295 (2003). (Pubitemid 36917699)
23. Alexander, J. H. et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomised controlled trial. JAMA 297, 1657-1666 (2007). (Pubitemid 46631624)
24. Ito, H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat. Clin. Pract. Cardiovasc. Med. 3, 499-506 (2006). (Pubitemid 44288463)
25. Ndrepepa, G. et al. 5 year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 55, 2383-2389 (2010).
26. Bolli R. Mechanism of myocardial stunning. Circulation 82, 723-738 (1990).
27. Reynolds, H. R. & Hochman, J. S. Cardiogenic shock: current concepts and improving outcomes. Circulation 117, 686-697 (2008).
28. Jennings, R. B. & Reimer K. A. Factors involved in salvaging ischemic myocardium: effect of reperfusion of arterial blood. Circulation 68 (Suppl. I), I25 I36 (1983).
29. Bonnefoy, E. et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 360, 825-829 (2002). (Pubitemid 35257945)
30. Asanuma T. et al. Relationship between progressive microvascular damage and intramyocardial hemorrhage in patients with reperfused anterior myocardial infarction. Myocardial Contrast Echocardiographic Study. Circulation 96, 448-453 (1997). (Pubitemid 27329419)
31. Babaev, A. et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 294, 448-454 (2005). (Pubitemid 41124177)
32. Antman, E. M. et al. ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110, e82-e292 (2004).
33. Westaby, S. Anastasiadis, K. & Wieselthaler, G. M. Cardiogenic shock complicating ACS. Part 2: role of mechanical circulatory support. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2011.205.
34. Birnbaum, Y., Fishbein, M. C., Blance, C. & Siegal, R. Ventricular septal rupture after acute myocardial infarction. N. Engl. J. Med. 347, 1426-1432 (2002). (Pubitemid 35239716)
35. Westaby, S., Parry, A., Ormerod, O., Gooneratne, P. & Pillai, R. Thrombolysis and post infarction ventricular septal rupture. J. Thorac. Cardiovasc. Surg. 104, 1506-1509 (1992). (Pubitemid 23001501)
36. Maltais, S. et al. Postinfarction ventricular septal defects: towards a new treatment algorithm. Ann. Thorac. Surg. 87, 687-692 (2009).
37. Moreyra, A. E. et al. Trends in incidence and mortality rates of ventricular septal rupture during acute myocardial infarction. Am. J. Cardiol. 106, 1095-1100 (2010).
38. The GUSTO investigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329, 673-682 (1993).
39. Yip, K. H. et al. The potential impact of primary cutaneous coronary intervention on ventricular septal rupture complicating acute myocardial infarction. Chest 125, 1622-1628 (2004).
40. Menon, V. et al. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: A report from the SHOCK trial registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J. Am. Coll. Cardiol. 36, 1110-1116 (2000).
41. Mann, J. M. & Roberts, W. C. Acquired ventricular septal defect during acute myocardial infarction: analysis of 38 unoperated necropsy patients and comparison with 50 unoperated necropsy patients without rupture. Am. J. Cardiol. 62, 8-19 (1988).
42. Prtre, R., Rickli, H., Ye, Q., Benedikt, P. & Turina, M. I. Frequency of collateral blood flow in the infarct-related coronary artery in rupture of the ventricular septum after acute myocardial infarction. Am. J. Cardiol. 85, 497-499 (2000). (Pubitemid 30089630)
43. Crenshaw, B. S. et al. Risk factors, angiographic patterns and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation 101, 27-32 (2000). (Pubitemid 30039072)
44. Poulsen, S. H. et al. Ventricular septal rupture complicating acute myocardial infarction: clinical characteristics and contemporary outcome. Ann. Thorac. Surg. 85, 1591-1596 (2008). (Pubitemid 351608174)
45. Ryan, T. J. et al. Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J. Am. Coll. Cardiol. 34, 890-911 (1999). (Pubitemid 29436200)
46. Mantovani, V. et al. Post-infarction cardiac rupture: surgical treatment. Eur. J. Cardiothorac. Surg. 22, 777-780 (2002). (Pubitemid 35300121)
47. Peuhkurinen, K., Risteli, L., Jounela, A. & Risteli, J. Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator. Am. Heart J. 131, 7-13 (1996). (Pubitemid 26021358)
48. Bueno, H., Martinez-Sélles, M., Pérez-David, E. & López-Palop, R. Effect of thrombolytic therapy on the risk of cardiac rupture and mortality in older patients with first acute myocardial infarction. Eur. Heart J. 26, 1705-1711 (2005). (Pubitemid 41219843)
49. Becker, A. E. & van Mantgem, J. P. Cardiac tamponade. A study of 50 hearts. Eur. J. Cardiol. 3, 349-358 (1975).
50. Figueras, J., Curos, A., Cortadellas, J. & Soler-Soler, J. Reliability of electromechanical dissociation in the diagnosis of left ventricular free wall rupture in acute myocardial infarction. Am. Heart J. 131, 861-864 (1996). (Pubitemid 26135746)
51. Railt, M. H., Kraft, C. D., Gardner, C. J., Pearlman, A. S. & Otto, C. M. Subacute ventricular free wall rupture complicating myocardial infarction. Am. Heart J. 126, 946-955 (1993). (Pubitemid 23291378)
52. Aymong, E. D., Ramanathan, K. & Buller, C. E. Pathophysiology of cardiogenic shock complicating acute myocardial infarction. Med Clin. North. Am. 91, 701-712 (2007). (Pubitemid 47058141)
53. Chevalier, P. et al. Perioperative outcome and long-term survival of surgery for acute post-infarction mitral regurgitation. Eur. J. Cardiothorac. Surg. 26, 330-335 (2004). (Pubitemid 39024654)
54. Tavakoli, R. et al. Results of surgery for irreversible moderate to severe mitral valve regurgitation secondary to myocardial infarction. Eur. J. Cardiothorac. Surg. 21, 818-824 (2002). (Pubitemid 34308939)
55. Hasdai, D. et al. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO III. Global use of Strategies to Open Occluded Coronary Arteries. Eur. Heart J. 20, 128-135 (1999). (Pubitemid 29048083)
56. Jolly, S. S. et al. Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events. Heart 97, 197-202 (2011).
57. Wong, S. C. et al. Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: A report from the SHOCK Trial registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J. Am. Coll. Cardiol. 36, 1077-1083 (2000).
58. Sanborn, T. A. et al. Impact of thrombolysis, intra-aortic balloon pump counter pulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J. Am. Coll. Cardiol. 36, 1123-1129 (2000).
59. Garcia-Alvarez, A. et al. Early risk stratification of patients with cardiogenic shock complicating acute myocardial infarction who undergo percutaneous coronary intervention. Am. J. Cardiol. 103, 1073-1077 (2009).
60. Sutton, A. G. et al. Predictors of outcome after percutaneous treatment for cardiogenic shock. Heart 91, 339-344 (2005). (Pubitemid 40299215)
61. Sleeper, L. A. et al. A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK trial and registry. Am. Heart J. 160, 443-450 (2010).
62. Den Uil, C. A. et al. Impaired microcirculation predicts poor outcome of patients with acute myocardial infarction complicated by cardiogenic shock. Eur. Heart J. 31, 3032-3039 (2010).
63. Tan L. B. Cardiac pumping capability and prognosis in heart failure. Lancet 328, 1360-1363 (1986). (Pubitemid 17191628)
64. Tan, L. B & Littler, W. A. Measurement of cardiac reserve in cardiogenic shock: implications for prognosis and management. Br. Heart J. 64, 121-128 (1990). (Pubitemid 20235997)
65. Finke, R. et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J. Am. Coll. Cardiol. 44, 340-348 (2004).
66. Mendoza, D. D., Cooper H. A. & Panza, J. A. Cardiac power output predicts mortality across a broad spectrum of patients with acute cardiac disease. Am Heart J 153, 366-370 (2007). (Pubitemid 46328753)
67. Menon, V. & Hochman, J. S. Management of cardiogenic shock complicating acute myocardial infarction. Heart 88, 531-537 (2002). (Pubitemid 35221973)
68. Bayram, M., De Luca, L., Massie, M. B. & Gheorghiade, M. Reassessment of dobutamine, dopamine and Milrinone in the management of acute heart failure syndromes. Am. J. Cardiol. 96, 47G-58G (2005). (Pubitemid 41338074)
69. De Backer, D. et al. Comparison of dopamine and norepinephrine in the treatment of shock. N. Engl. J. Med. 362, 779-789 (2010).
70. Lahm, T. et al. Medical and surgical treatment of acute right heart failure. J. Am. Coll. Cardiol. 56, 1435-1446 (2010).
71. Jardin, F. & Vieillard-Baron, A. Right ventricular function and positive pressure ventilation in clinical practice: from hemodynamic subsets to respirator settings. Intensive Care Med. 29, 1426-1434 (2003). (Pubitemid 37158027)
72. George, I. et al. Clinical indication for use and outcomes after inhaled nitric oxide therapy. Ann. Thorac. Surg. 82, 2161-2169 (2006).
73. Vizza, C. D. et al. Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit. Care 5, 355-361 (2001). (Pubitemid 34130338)
74. Hentschel, T. et al. Inhalation of the phosphodiesterase 3 inhibitor milrinone attenuates pulmonary hypertension in a rate model of congestive heart failure. Anesthesiology 106, 124-131 (2007). (Pubitemid 46035412)
75. Kerbaul, F. et al. Effects of levosimendan versus dobutamine on pressure-load induced right ventricular failure. Crit. Care Med. 34, 2814-2819 (2006). (Pubitemid 44610948)
76. Lepore, J. J. et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 127, 1647-1653 (2005). (Pubitemid 46218790)
77. Garot, P., Bendaoud N., Lefèvre, T. & Morice, M. C. Favorable effect of statin therapy on early survival benefit at the time of percutaneous coronary intervention for ST elevation myocardial infarction and shock. EuroIntevention 6, 350-355 (2010).
78. Albert, M. A., Danielson, E., Rifai, N. & Ridker, P. K. for the PRINCE Investigators. Effect of statin therapy on C reactive protein levels: the pravastatin inflammation /CRP evaluation (PRINCE): a randomised trial and cohort study. JAMA 286, 64-70 (2001). (Pubitemid 32606333)
79. Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N. Engl. J. Med. 335, 1001-1009 (1996). (Pubitemid 26338729)
80. Hoffmann, R. et al. Effect of statin therapy before Q wave myocardial infarction on myocardial perfusion. Am. J. Cardiol. 101, 139-143 (2008).
81. Aronow, H. D. et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 357, 1063-1068 (2001). (Pubitemid 32322536)
82. Strandberg, T. E., Vanhanen, H. & Tikkanen, M. J. Effect of stains on C reactive protein in patients with coronary disease. Lancet 353, 118-119 (1999). (Pubitemid 29088085)
83. Stenestrand, U. & Wallentin, L. for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardialinfarction and 1-year survival. JAMA 285, 430-436 (2001). (Pubitemid 32097261)
84. Heeschen, C. et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105, 1446-1452 (2002). (Pubitemid 34263276)
85. Briel, M. et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 295, 2046-2056 (2006). (Pubitemid 44794006)
86. Gwinnutt, C. L., Columb, M. & Harris R. Outcome after cardiac arrest in adults in UK hospitals: effect of the 1997 guidelines. Resuscitation 47, 125-135 (2000).
87. Polderman, K. H. Application of therapeutic hypothermia in the ICU: opportunities and pitfalls of a promising treatment modality. Part 1: indications and evidence. Intensive Care Med. 30, 556-575 (2004). (Pubitemid 38530090)
88. Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N. Engl. J. Med. 346, 549-556 (2002).
89. Benson, D. W., Williams, G. R. Jr., Spencer, F. C. & Yates, A. J. The use of hypothermia after cardiac arrest. Anesth. Analg. 38, 423-428 (1959).
90. Bigelow, W. G., Lindsay, W. K. & Greenwood, W. F. Hypothermia; its possible role in cardiac surgery: an investigation of factors governing survival in dogs at low body temperatures. Ann. Surg. 132, 849-866 (1950).
91. Bernard SA. et al. Treatment of comatose survivors of out of hospital cardiac arrest with induced hypothermia. N. Engl. J. Med. 346, 557-563 (2002). (Pubitemid 34438816)
92. Nolan, J. P. et al. Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation. Circulation 108, 118-121 (2003). (Pubitemid 36859031)
93. Nolan, J. P., Deakin, C. D., Soar, J., Böttiger, B. W. & Smith, G. European Resuscitation Council Guidelines for Resuscitation 2005. Section 4. Adult advanced life support. Resuscitation 67 (Suppl. I), S39-S86 (2005). (Pubitemid 41729023)
94. Polderman, K. H. Application of therapeutic hypothermia in the intensive care unit. Opportunities and pitfalls of a promising treatment modality-Part 2: Practical aspects and side effects. Intensive Care Med. 30, 757-769 (2004). (Pubitemid 38639465)